retatrutide type 2 diabetes trial results 2024 ESC 2024: improves lipid and cardiovascular risk profile in Phase II Retatrutide: The Triple Agonist That's

This simplified the trial design but raises legitimate questions about whether weight-based dosing might improve outcomes

Past and current GLP-1 users (46% and 43%, respectively) were more likely to do so than non-users (25%)

These expanded studies will test the medication in larger and more diverse populations, assess longer-term outcomes, and provide the data required for regulatory approval submissions to both the FDA and Health Canada

Electrolyte supplementation can help manage the transition period

Well cover what bloodwork you need before and during GLP-1 treatment to navigate the journey confidently

strongerthe pros and cons to help you choose